Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Sep 20;294(38):13876-13886.
doi: 10.1074/jbc.RA119.009213. Epub 2019 Aug 6.

A strategy for the selection of monovalent antibodies that span protein dimer interfaces

Affiliations

A strategy for the selection of monovalent antibodies that span protein dimer interfaces

Jamie B Spangler et al. J Biol Chem. .

Abstract

Ligand-induced dimerization is the predominant mechanism through which secreted proteins activate cell surface receptors to transmit essential biological signals. Cytokines are a large class of soluble proteins that dimerize transmembrane receptors into precise signaling topologies, but there is a need for alternative, engineerable ligand scaffolds that specifically recognize and stabilize these protein interactions. Recombinant antibodies can potentially serve as robust and versatile platforms for cytokine complex stabilization, and their specificity allows for tunable modulation of dimerization equilibrium. Here, we devised an evolutionary strategy to isolate monovalent antibody fragments that bridge together two different receptor subunits in a cytokine-receptor complex, precisely as the receptors are disposed in their natural signaling orientations. To do this, we screened a naive antibody library against a stabilized ligand-receptor ternary complex that acted as a "molecular cast" of the natural receptor dimer conformation. Our selections elicited "stapler" single-chain variable fragments (scFvs) of antibodies that specifically engage the interleukin-4 receptor heterodimer. The 3.1 Å resolution crystal structure of one such stapler revealed that, as intended, this scFv recognizes a composite epitope between the two receptors as they are positioned in the complex. Extending our approach, we evolved a stapler scFv that specifically binds to and stabilizes the interface between the interleukin-2 cytokine and one of its receptor subunits, leading to a 15-fold enhancement in interaction affinity. This demonstration that scFvs can be selected to recognize epitopes that span protein interfaces presents new opportunities to engineer structurally defined antibodies for a broad range of research and therapeutic applications.

Keywords: antibody engineering; cell signaling; cytokine; dimerization; directed evolution; immunology; interleukin-2; interleukin-4; ligand-receptor interactions; structural biology.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest with the contents of this article

Figures

Figure 1.
Figure 1.
Novel evolutionary selection strategy isolates antibody-based “staplers” that dimerize cytokine receptor chains. A, schematic contrasting receptor heterodimerization and activation induced by cytokine, antibody, or “stapler” scFv binding, respectively. B, layout and selection scheme for yeast display-based evolution of cytokine–receptor complex staplers. A yeast-displayed scFv library is evolved through iterative rounds of selection, each of which comprises negative clearance steps against the individual complex components and positive selection for binders to the fully assembled ternary complex. C, flow cytometry histograms depicting the binding of yeast-displayed IL-4 stapler scFv to the indicated cytokine–receptor complexes and individual components thereof. TC, ternary complex. D, kinetic SPR binding profiles for the interactions between the immobilized IL-4 stapler scFv and soluble Super-4/IL-4Rα/γc TC components versus the fully assembled complex. All proteins were flowed at a concentration of 60 μm. E, surface plasmon resonance kinetic binding traces depicting the interaction between immobilized IL-4 stapler scFv and dilutions of the Super-4/Il-4Rα/γc ternary complex. The equilibrium dissociation constant (KD) value was calculated by fitting the equilibrium titration curve to a logistic model via nonlinear regression. The top curve represents a concentration of 20 μm, and subsequent curves represent 3-fold serial dilutions.
Figure 2.
Figure 2.
Stapler recognizes a composite epitope between two receptor subunits to bridge the dimer interface. A, orthosteric views of the crystallographic structure of the IL-4 stapler Fab fragment bound to the Super-4/IL-4Rα/γc ternary complex. B, enlarged views of the IL-4 stapler interfaces with the IL-4Rα and γc subunits. At the left, IL-4 stapler-binding sites on IL-4Rα and γc are depicted in gray, with interacting residues in the CDRs of the VH (magenta) and VL (olive) domains of the IL-4 stapler Fab shown as sticks. At the right, the CDRs on VH (magenta) and VL (olive) of the IL-4 stapler Fab are shaded.
Figure 3.
Figure 3.
Evolved staplers specifically engage cytokine–receptor binary complex with engineerable affinity. A, schematic contrasting sequential assembly of a cytokine–receptor ternary complex in the absence (top) or presence (bottom) of a binary complex–stabilizing stapler scFv. B, yeast display platform diagram and selection strategy for evolution of cytokine–receptor binary complex stapler scFvs. C, binding of yeast-displayed IL-2B (left) or amIL-2B (right) stapler scFv to cytokine–receptor complexes and individual components thereof. Note the selective recognition of the IL-2/IL-2Rβ binary complex and compatibility with γc binding. TC, ternary complex. D, kinetic surface plasmon resonance binding profiles for the IL-2B stapler:IL-2 BC (left) and amIL-2B stapler:IL-2 BC (right) interactions. As shown in the traces, the affinity-matured stapler variant improves affinity 14-fold through deceleration of the dissociation rate. KD values were calculated by fitting equilibrium titration curves to a logistic model via nonlinear regression.
Figure 4.
Figure 4.
Binary complex staplers strengthen cytokine–receptor interactions to potentiate signaling of an affinity-impaired cytokine variant. A, equilibrium surface plasmon resonance titrations of the IL-2:IL-2Rβ binary complex interaction without scFv present (filled blue circles) and with IL-2BC stapler scFv (gold circles) or amIL-2B stapler scFv (cyan circles) compared with the Super-2:IL-2Rβ interaction (unfilled blue circles). KD values were calculated by fitting equilibrium titration curves to a logistic model via nonlinear regression. IL-2B staplers increase the IL-2:IL-2Rβ interaction affinity ∼15-fold. B, YT-1 cell STAT5 phosphorylation responses to impaired affinity IL-2 (iIL-2) without scFv present (filled blue circles) and with saturating levels of IL-2B stapler (gold circles) or amIL-2B stapler (cyan circles) present compared with WT IL-2 (unfilled blue circles). EC50 values are indicated. Error bars, S.D.

Comment in

References

    1. Ullrich A., and Schlessinger J. (1990) Signal transduction by receptors with tyrosine kinase activity. Cell 61, 203–212 10.1016/0092-8674(90)90801-K - DOI - PubMed
    1. Klemm J. D., Schreiber S. L., and Crabtree G. R. (1998) Dimerization as a regulatory mechanism in signal transduction. Annu. Rev. Immunol. 16, 569–592 10.1146/annurev.immunol.16.1.569 - DOI - PubMed
    1. Wang X., Lupardus P., Laporte S. L., and Garcia K. C. (2009) Structural biology of shared cytokine receptors. Annu. Rev. Immunol. 27, 29–60 10.1146/annurev.immunol.24.021605.090616 - DOI - PMC - PubMed
    1. Bazan J. F. (1989) A novel family of growth factor receptors: a common binding domain in the growth hormone, prolactin, erythropoietin and IL-6 receptors, and the p75 IL-2 receptor β-chain. Biochem. Biophys. Res. Commun. 164, 788–795 10.1016/0006-291X(89)91528-3 - DOI - PubMed
    1. Rochman Y., Spolski R., and Leonard W. J. (2009) New insights into the regulation of T cells by γ(c) family cytokines. Nat. Rev. Immunol. 9, 480–490 10.1038/nri2580 - DOI - PMC - PubMed

Publication types